-
Mashup Score: 17Basic Researchers Discover Possible Target for Treating Brain Cancer - 10 month(s) ago
Over the years, cancer researchers have uncovered many of the tricks that tumors use to fuel their growth and evade detection by the body’s immune system. More tricks await discovery, and finding t…
Source: NIH Director's BlogCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Glioblastoma heterogeneity at single cell resolution - Oncogene - 11 month(s) ago
Glioblastoma (GBM) is one of the deadliest types of cancer and highly refractory to chemoradiation and immunotherapy. One of the main reasons for this resistance to therapy lies within the heterogeneity of the tumor and its associated microenvironment. The vast diversity of cell states, composition of cells, and phenotypical characteristics makes it difficult to accurately classify GBM into…
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A fantastic review from @YAlanWang on #glioblastoma heterogeneity shedding light on the challenges in designing clinical trials for #GBM patients. 🔬https://t.co/YaIsRtKcBg
-
-
Mashup Score: 2UCPVax Prompts Immune Responses in MGMT Unmethylated Glioblastoma - 11 month(s) ago
UCPVax, an anti-telomerase vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with MGMT unmethylated glioblastoma.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
UCPVax induced strong and durable responses against TERT in patients with MGMT unmethylated glioblastoma. #ASCO23 #gbm https://t.co/UffIhUbMrC
-
-
Mashup Score: 7GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity - Nature Cancer - 11 month(s) ago
Watson et al. demonstrate that astrocyte mitochondria can be horizontally transferred to glioblastoma cells in a GAP43-dependent manner, leading to changes in mitochondrial respiration and metabolism that promote proliferation and tumor growth.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
Way to go @d_bayik & @DionysiosWatson @SylvesterCancer for being featured on @NatureCancer cover with this artistic rendering of intercellular mitochondrial transfer in #GBM! https://t.co/7UZZ1rrZ1U https://t.co/8PN4yYpO4F
-
-
Mashup Score: 1White House Cancer Moonshot Forum on Brain Cancers - 11 month(s) ago
On Thursday, May 25, 2023, the White House Cancer Moonshot will convene patients, caregivers, oncologists, researchers, and administration officials to advan…
Source: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful comments by @LisaWardspeakup in the opening session of the @WHOSTP #CancerMoonshot #BrainTumor Forum streaming right now ⬇️ https://t.co/sz19wSOnLL #DIPG #GBM #GoGrayInMay #ChildhoodCancer #OncTwitter
-
-
Mashup Score: 9Basic Researchers Discover Possible Target for Treating Brain Cancer - 12 month(s) ago
Over the years, cancer researchers have uncovered many of the tricks that tumors use to fuel their growth and evade detection by the body’s immune system. More tricks await discovery, and finding t…
Source: NIH Director's BlogCategories: Healthcare Professionals, Latest HeadlinesTweet-
#Glioblastoma #braincancers grow more aggressively after taking energy-generating components from other cells. What it could mean for new #GBM cancer treatments on the NIH Director’s Blog. https://t.co/MwUdkb9kdM
-
-
Mashup Score: 5
A team led by Northwestern Medicine investigators have discovered novel cellular mechanisms that lead to chemotherapy resistance in recurrent glioblastoma, according to findings published in Science Advances.
Source: News CenterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A multi-institution team led by @LurieCancer member @atiqueahmedphd has discovered novel cellular mechanisms that lead to chemotherapy resistance in recurrent #glioblastoma, according to findings published in @ScienceAdvances. https://t.co/ZW4aOqfdEz #BTSM #GBM #BTAM https://t.co/wAxl1549nU
-
-
Mashup Score: 2Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial - Nature Medicine - 12 month(s) ago
A safety and efficacy trial of a single intratumoral dose of the oncolytic adenovirus DNX-2401 followed by intravenous anti-PD-1 pembrolizumab in patients with recurrent glioblastoma shows an encouraging clinical benefit rate and 12 months overall survival.
Source: NatureCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @gelarehzadeh: Excited to share our paper #Clinicaltrial #GBM https://t.co/eYBk11xoZV @NatureMedicine Improved survival 50% #oncolyti…
-
-
Mashup Score: 0
Two genetically engineered gamma-delta T-cell therapies, INB-400 and INB-410, have been granted an orphan drug designation from the FDA for numerous types of malignant glioma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has granted an orphan drug designation to INB-400 and INB-410, for the treatment of a broad range of malignant #glioma, including newly diagnosed glioblastoma multiforme. #GBM https://t.co/kx1gEoFt10
-
-
Mashup Score: 0Brain Tumor Awareness Month 2023 | Pacific Neuro Institute - 1 year(s) ago
May is Brain Tumor Awareness Month. “Go Gray in May” and celebrate our patients, their loved ones, and their important journeys.
Source: Pacific Neuroscience InstituteCategories: Hem/Oncs, Latest HeadlinesTweet-
Stay tuned for more and find other resources https://t.co/jQDkO3TGuv @PacificNeuroPNI #BrainTumorAwarenessMonth #braintumor #braincancer #glioma #gbm
-
Researchers have found that #glioblastoma cells may steal mitochondria from other cells. The finding suggests a possible strategy for treating brain tumors, the Acting @NIHDirector writes on his blog. https://t.co/t7Txb91e9v #GBM #CancerResearch